BOGGIANI, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 353
EU - Europa 280
AS - Asia 187
SA - Sud America 21
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 850
Nazione #
US - Stati Uniti d'America 348
SG - Singapore 95
IE - Irlanda 94
CN - Cina 79
SE - Svezia 62
IT - Italia 50
DE - Germania 27
BR - Brasile 20
BE - Belgio 7
FI - Finlandia 7
GB - Regno Unito 7
RU - Federazione Russa 7
CI - Costa d'Avorio 6
CZ - Repubblica Ceca 5
AT - Austria 4
CA - Canada 4
IN - India 4
LT - Lituania 4
TR - Turchia 4
FR - Francia 2
NL - Olanda 2
A1 - Anonimo 1
ES - Italia 1
HK - Hong Kong 1
IL - Israele 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
SN - Senegal 1
Totale 850
Città #
Chandler 94
Dublin 94
Singapore 56
Santa Clara 50
Shanghai 29
Beijing 26
Boardman 19
Ashburn 17
Bremen 12
New York 12
Princeton 12
Seattle 12
Ann Arbor 11
Parma 10
Dearborn 8
Des Moines 8
Wilmington 8
Brussels 7
Helsinki 7
Ravenna 7
Abidjan 6
Los Angeles 5
Nuremberg 5
Ardea 4
Cascina 4
Moscow 4
Olomouc 4
Bologna 3
Frankfurt am Main 3
Verona 3
Brooklyn 2
Falls Church 2
Fremont 2
London 2
Marseille 2
Munich 2
Nanchang 2
Pavia 2
Rio Saliceto 2
Rome 2
Toronto 2
Almaty 1
Amsterdam 1
Anajatuba 1
Bauru 1
Belo Horizonte 1
Berlin 1
Blumenau 1
Campinas 1
Campos dos Goytacazes 1
Canoinhas 1
Caxias do Sul 1
Colombo 1
Curitiba 1
Curvelo 1
Dakar 1
Dracena 1
Edinburgh 1
Fairfield 1
Fernando de la Mora 1
Guangzhou 1
Hangzhou 1
Hebei 1
Huizen 1
Istanbul 1
Izmir 1
Jiaxing 1
João Pessoa 1
Kocaeli 1
Kunming 1
Madrid 1
Milan 1
Modena 1
Montreal 1
Muscat 1
Osasco 1
Ottawa 1
Panama City 1
Paulista 1
Phoenix 1
Piacenza 1
Porto Velho 1
Prague 1
Pune 1
Rabat 1
Raul Soares 1
Redwood City 1
Riga 1
Rio de Janeiro 1
Rockville 1
Shenyang 1
Shenzhen 1
Stockholm 1
São Paulo 1
Taglio Di Po 1
Taizhou 1
Tel Aviv 1
Tianjin 1
Turmalina 1
Vienna 1
Totale 621
Nome #
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 78
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 71
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 70
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 69
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 66
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 63
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 56
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 55
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations 54
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 53
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 53
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 51
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 43
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 37
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study 31
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 25
Totale 875
Categoria #
all - tutte 4.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.564


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202043 0 0 0 0 0 0 0 0 1 34 8 0
2020/202143 2 5 0 3 3 6 9 7 4 2 1 1
2021/202244 0 1 5 0 2 0 3 4 1 0 1 27
2022/2023315 25 34 19 22 34 33 2 23 112 1 8 2
2023/2024137 2 14 1 2 3 22 10 22 4 18 22 17
2024/2025274 23 20 25 29 46 40 17 23 51 0 0 0
Totale 875